These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: GMP-Automated Purification of Copper-61 Produced in Cyclotron Liquid Targets: Methodological Aspects.
    Author: Fonseca AI, Alves VH, do Carmo SJC, Falcão A, Abrunhosa AJ, Alves F.
    Journal: Curr Radiopharm; 2021; 14(4):420-428. PubMed ID: 33183218.
    Abstract:
    BACKGROUND: Expanding the range of metal-based PET radiopharmaceuticals that can be produced by the widely available network of biomedical cyclotrons is a major priority. Copper- 61 is a positron emitter with very favourable physical (61.5% β+, 1.22 MeV max.) and chemical properties, which emerged as a promising PET imaging agent. OBJECTIVES: This work aimed to develop and optimise a GMP-automated purification method for copper-61 produced in a cyclotron using a natural zinc liquid target. METHODS: The automated purification process was performed using a commercially available Synthera ® Extension module (IBA, Louvain-la-Neuve, Belgium) using a three-column method: two extraction chromatographic resins and a strong anion exchange resin. The final product was evaluated using HPGe and ICP-MS analysis, to assess the radionuclidic and chemical purity of the final copper- 61 solution. RESULTS: The automated purification process was completed within 1 h of processing time, with an average yield of 63.0 ± 15.0%, in a maximum volume of 5 mL. The radionuclidic purity of copper- 61 in the final solution was over 95% for 7 h after EOB. ICP-MS analysis revealed 4.8 ± 2.4 μg of natural zinc in the final purified sample, and the copper-61 molar activity was 230.5 ± 139.3 GBq/μmol. CONCLUSION: The described purification process allows for the production of a highly radionuclidically and chemically pure, GMP compliant copper-61 solution, ready to be used for the development of copper-61 based radiopharmaceuticals for routine clinical use.
    [Abstract] [Full Text] [Related] [New Search]